REPROCELL offers iPSC-derived exosome production service at our GMP-compliant manufacturing facility in Japan for clients seeking high-quality vesicles for preclinical research. We also provide ready-to-use, highly purified and concentrated exosomes produced from our StemRNA Clinical iPSC Clones.
Clinical Stem Cell Services
iPSC-Derived Exosome Production Service
iPSC-derived exosomes are emerging as a highly scalable and customizable platform for next-generation extracellular vesicle therapies. iPSCs offer an ethically straightforward, readily sourced starting material that supports consistent large-scale manufacturing, advanced cargo engineering, and precise surface customization.
Recent studies show that iPSC-derived exosomes deliver strong regenerative and anti-senescence effects across multiple tissues, including skin, eye, vascular, and musculoskeletal systems, often outperforming MSC-derived exosomes (Wang et al., 2020). With broad therapeutic potential and unmatched flexibility, iPSC-derived exosomes are rapidly becoming a leading candidate for innovative, cell-free regenerative medicine.
Find out more about iPSC-derived Exosomes:
Some therapeutic areas where iPSC-derived exosomes are being investigated
(Wang et al., 2021):
- Cardiovascular Disease
- Moyamoya Disease
- Liver Disease
- Ischemic limb disease
- Bone Disease (bone defects, osteonecrosis and osteonecrosis)
- Eye Disease (Corneal epithelial defects)
- Neurological Disease (Alzheimer’s disease, Rett syndrome, Bipolar I disorder)
- Skin Disease (wound healing)
iPSC-Derived Exosome Manufacturing Services for Preclinical Research
Why Choose REPROCELL Japan GMP Manufacturing Facility?
iPSC-derived exosome manufacturing takes place at REPROCELL’s GMP facility in Tonomachi, Japan. The center operates under Japan’s Act on the Safety of Regenerative Medicine and maintains a certified quality management system for clinical-grade cell product manufacturing. Production takes place in rigorously controlled cleanroom environments featuring monitored air quality, aseptic processing, and strict environmental oversight. With experience supporting advanced cell-based products, including StemRNA Clinical iPSC Clones and TIL (Tumor-Infiltrating Lymphocytes) for clinical research, the facility provides a reliable foundation for producing high-quality iPSC-derived exosomes for research and clinical development.
Let’s collaborate:
Discover how we can take your exosome and vesicle programmes from development to GMP manufacturing with Japanese quality and global regulatory readiness. Contact us via the inquiry form.
Ready-to-use iPSC-derived Exosomes
We also offer off-the-shelf, high-purity exosomes derived from our StemRNA™ Clinical iPSC Clones. These iPSC-derived exosomes are produced at our REPROCELL Japan GMP Manufacturing Facility, and are available worldwide for preclinical and advanced research applications. These two products are ideal for studying anti-aging and collagen production. They are available in a liquid or lyophilized form.

iPSC Purified Exosomes
(Liquid)
RCEV002

iPSC Purified Exosomes (Lyophilized)
RCEVLY001
Please contact us for more information
Discover more
Resources
- FAQ: Clinical iPSCs
- FAQ: Clinical MSCs
- FAQ: iPSC-Derived Exosomes
- Making iPSC-Derived Therapeutics a Clinical Reality – our external article in the European Biopharmaceutical Review.
Gene Editing Services
